Oral Estradiol Month-by-Month: Real Results in the First 3 Months

What the label sets out for the first three months

The oral estradiol label gives a usual initial dose of 1 to 2 mg daily, adjusted as needed to control presenting symptoms, with administration cyclic, for example three weeks on and one week off [2]. The label says a progestin should also be started in a postmenopausal woman with a uterus, and that a woman without a uterus does not need one [2].

The label's checkpoints are reassessment every 3 to 6 months and attempts to taper or stop at 3- to 6-month intervals [2].

Bleeding in the first three months

Bleeding data for estradiol in this window come from a combination tablet. In a 48-week double-blind trial of 572 women, vaginal bleeding occurred during the first 3 months in 33.1 percent of those taking oral estradiol 1 mg plus norethisterone acetate 0.5 mg, against 18.3 percent on tibolone [1]. In the same trial, vasomotor symptoms and vaginal atrophy were significantly reduced in both treatment groups, to a similar extent [1]. Those figures belong to a two-drug tablet, not to estradiol alone.

The labels treat bleeding as a signal: undiagnosed abnormal genital bleeding is a contraindication, and persistent or recurring abnormal genital bleeding should be evaluated, including endometrial sampling when indicated, to rule out malignancy [2][3].

Side effects: what is listed and what is counted

The oral label lists reactions reported with estrogen therapy without frequencies: breast tenderness, enlargement and pain; nausea, vomiting, abdominal cramps and bloating; headache, migraine and dizziness; changes in vaginal bleeding; edema; weight change; mood changes; gallbladder disease; chloasma; and increased blood pressure [2].

Counted rates come from a patch label, not the tablet label. In the Climara estradiol transdermal trials, breast pain was reported by 8 percent of women on 0.05 mg per day and 29 percent on 0.1 mg per day over 3 months, against 4 percent on placebo; headache by 18 and 13 percent against 10 percent; abdominal pain by 11 and 16 percent against 8 percent [3]. Those are patch figures and do not describe oral tablets.

Clot risk in the first months

In the observational studies included in one systematic review, the odds ratio for a first venous thromboembolism was 2.5 (95% CI 1.9 to 3.4) with oral estrogen and 1.2 (0.9 to 1.7) with transdermal estrogen [4]. Within that observational analysis, the oral-estrogen odds ratio was 4.0 (95% CI 2.9 to 5.7) in the first year of use and 2.1 (1.3 to 3.8) after more than one year [4]. The review also included nine randomized trials, which reported separate estimates; the pooled randomized estimate for oral estrogen was an odds ratio of 2.1 (95% CI 1.4 to 3.1) [4]. None of these estimates is specific to oral estradiol tablets.